Expression of TRX1 optimizes the antitumor functions of human CAR T cells and confers resistance to a pro-oxidative tumor microenvironment

Use of chimeric antigen receptor (CAR) T cells to treat B cell lymphoma and leukemia has been remarkably successful. Unfortunately, the therapeutic efficacy of CAR T cells against solid tumors is very limited, with immunosuppression by the pro-oxidative tumor microenvironment (TME) a major contribut...

Descripción completa

Detalles Bibliográficos
Autores principales: Balta, Emre, Janzen, Nina, Kirchgessner, Henning, Toufaki, Vasiliki, Orlik, Christian, Liang, Jie, Lairikyengbam, Divya, Abken, Hinrich, Niesler, Beate, Müller-Decker, Karin, Ruppert, Thomas, Samstag, Yvonne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794734/
https://www.ncbi.nlm.nih.gov/pubmed/36591284
http://dx.doi.org/10.3389/fimmu.2022.1063313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794734/
https://www.ncbi.nlm.nih.gov/pubmed/36591284
http://dx.doi.org/10.3389/fimmu.2022.1063313

Ejemplares similares